SCHEMBL23218230

SCHEMBL23218230

CCOC(=O)Cc1ccc(C(N)=O)cc1OCc1coc2ccc(Br)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.43
HTR1D P28221 2/20 0.43
HTR2C P28335 2/20 0.43
MTNR1B P49286 1/20 0.41
KMT2A Q03164 4/20 0.37
MAPT P10636 3/20 0.37
PTGER1 P34995 1/20 0.37
MEN1 O00255 3/20 0.36
POLB P06746 2/20 0.36
GAA P10253 1/20 0.36
NQO2 P16083 1/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
MTNR1A P48039 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852918 1.00 HTR1A (0.43) HTR1AHTR1DHTR2CMTNR1BKMT2A
SCHEMBL23218987 0.91 MAPT (0.40) KMT2AMAPTMEN1POLBGAA
SCHEMBL29852463 0.91 MAPT (0.40) KMT2AMAPTMEN1POLBGAA
SCHEMBL29852736 0.88 MAPT (0.45) KMT2AMAPTMEN1POLBGAA
SCHEMBL23218720 0.88 MAPT (0.45) KMT2AMAPTMEN1POLBGAA
SCHEMBL23218144 0.87 KMT2A (0.40) KMT2AMAPTMEN1POLBGAA
SCHEMBL29592675 0.87 KMT2A (0.40) KMT2AMAPTMEN1POLBGAA
SCHEMBL23218975 0.87 MAPT (0.42) KMT2AMAPTMEN1POLBGAA
SCHEMBL23218045 0.86 MAPT (0.43) MTNR1BKMT2AMAPTMEN1POLB
SCHEMBL29852601 0.86 MAPT (0.43) MTNR1BKMT2AMAPTMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB HTR1A 2107/4885HTR1D 932/4885HTR2C 1202/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB HTR1A 3260/4885HTR1D 1365/4885HTR2C 3872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.